StonvexLoading…
StonvexStonvexStonvexCore line items from ONMD's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $96.00K | $1.36M | $468.00K | $292.00K |
Operating Income | $-2.55M | $-9.67M | $-6.58M | $-4.35M |
Net Income | $-2.45M | $-2.80M | $339.00K | $2.98M |
EPS (Diluted) | $-0.04 | $-0.06 | $0.01 | $0.03 |
Total Assets | $1.51M | $2.15M | $1.51M | $2.34M |
Total Liabilities | $5.59M | $5.12M | $5.45M | $6.18M |
Cash & Equivalents | $233.00K | $585.00K | $149.00K | $122.00K |
Free Cash Flow OCF − CapEx | $-1.54M | $-7.52M | $-5.80M | $-4.24M |
Shares Outstanding | 52.79M | 51.80M | 49.73M | 46.10M |